Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression

• DOI: 10.1172/jci.insight.93098
• Publication Date: 2017-05-17T15:00:52Z
• Authors: James T. Thackeray; Stefan Pietzsch; Britta Stapel; Melanie Ricke-Hoch; Chun-Wei Lee; Jens P. Bankstahl; Michaela Scherr; Jörg Heineke; Gesine Scharf; Arash Haghikia; Frank M. Bengel; Denise Hilfiker-K...
• Keywords: Insulin oscillation

Advanced cancer induces fundamental changes in metabolism and promotes cardiac atrophy heart failure. We discovered systemic insulin deficiency cachectic patients. Similarly, mice with advanced B16F10 melanoma (B16F10-TM) or colon 26 carcinoma (C26-TM) displayed decreased associated marked atrophy, metabolic impairment, function. C26 tumors decrease via high glucose consumption, lowering pancreatic production producing insulin-degrading enzyme. As tumor cells consume an insulin-independent manner, they shift away from cardiomyocytes. Since cardiomyocytes both models remained responsive, low-dose supplementation by subcutaneous implantation of insulin-releasing pellets improved uptake, function, no adverse side effects. In addition, redirecting to the addition other organs, treatment lowered usage thereby growth volume. Insulin corrected cancer-induced reduction Akt activation subsequent overactivation proteasome autophagy. Thus, depletion contributes wasting failure may promote growth. Low-dose attenuates these processes be supportive cardio-oncologic concepts.